Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
SNO Digest spreading lies
2023 SNO Clinical Trial Design Workshop – Apply Now!
The Society for Neuro-Oncology is pleased to announce the 5th Annual Introduction to Clinical Trial Design and Protocol Development Workshop. This year’s workshop will be held in person on Wednesday, November 15, 2023 in Vancouver, Canada, the day before the 28th Annual Meeting and Education Day.
A total of up to 100 participants will be selected to attend the workshop through a competitive application process, with up to 75 participants selected for Group 1 and up to 25 participants selected for Group 2. Applicants will select their preferred Group in the application, but the Course Planning Committee reserves the right to make final Group selections for each participant. For full information, please click here.
Head to the Hill 2023
Dr. Ashley Margol welcomed delegates to the NBTS Head to the Hill event on behalf of SNO
SNO was represented at Head to the Hill this year by (L to R) Sasmit Sarangi, Shelley Pressley, Soma Sengupta, Mahua Dey, Yasmin Nelson, and Dylan Pasiuk.
This week SNO members joined the National Brain Tumor Society and over 400 patients, caregivers, and professionals at the 2023 Head to the Hill event to speak with one voice to educate lawmakers and advocate for policy change. Advocates asked for more brain tumor funding at the NIH and NCI, appropriate funding for the Peer-Reviewed Cancer Research Program at the DOD, and urged members of Congress to co-sponsor and pass the Stop the Wait Act (H.R. 883 /S. 320). A special thanks to NBTS for organizing this impactful event, Dr. Ashley Margol for speaking on SNO’s behalf, and the SNO members who represented the Society on Capitol Hill!
From The Journals
From Neuro-Oncology
Autologous tumor lysate-loaded dendritic cell vaccination (DCVax-L) in glioblastoma: Breakthrough or fata morgana?
Glioblastoma is the most common malignant primary brain tumor of adults and associated with high morbidity and mortality. Increased biological insights have so far not translated into new treatments and the current standard of care therapy for newly diagnosed glioblastoma comprises maximal safe resection and radiochemotherapy with temozolomide, while no treatment standard exists for recurrent disease.1 Molecularly directed treatments such as EGFR inhibition, integrin inhibition, VEGF inhibition, immune checkpoint inhibitors and others have failed to show clinical benefit in prospective randomized clinical trials. Recently, Liau et al2 reported data on autologous tumor lysate-loaded dendritic cell vaccination (DCVax-L) in JAMA Oncology on November 17, 2022 and at the 27th Society of Neuro-Oncology (SNO) Annual meeting on November 20, 2022. While the efforts of all contributors to the study need to be acknowledged, there are significant concerns about the study report and conclusions. Click here to read the full article.
Waiting for approval........
Following Approval, the world is our oyster. BMY, MRK, ?
The only difference between the two treatments is that DCVax-L has real long term data to support it extends life. NVCR's data was cut off at 2 years and is a bunch of projections that the patient would have lived 5 years. It's nothing but liars math. This is why the NVCR executives are selling their stock and NWBO's executives are buying stock.
Let's see if you folks can control the SP after approval and after the Law suit. I see this SP as a wonderful buying opportunity funded by the 7 morally bankrupt firms.
I'm confident you don't have the credentials of one of the Journals 70 Coauthors supporting the treatment. DCVax-L works alone with all types of tumors. Granted it is more effective with specific types of tumors. This said, the data results with Keytruda are beyond belief so the initial results will not really matter after approval. We will end up with several combination therapies.
Money without foresight is useless. If this was not true IBM would be huge and Microsoft would not exist.
If you were on the approval committee looking at a 13% vs 5% survival rate after years of absolutely no progress, you would approve DCVax-L. Furthermore, if you were on the committee and you see preliminary data indicating a 50% survival rate in a couple of years or so. You would Definitely without a doubt approve DCVax-L. As without approval of DCVax-L you would be condemning thousands to death and stifling this amazing step forward in Cancer treatment. No RA will turn it's head on the preliminary results.
It depends on what information you are seeking. There are many posters on this board that know more than I ever will about tumors, law, charting, BP, Regulatory Authorities, and other items. After reading many posts, one can quickly determine who is knowledgeable and who is trying to mislead you. While the road has been longer than I ever expected, I have learned a lot from the poster on this very board.
Nice post. You are correct. Many shorts are pounding away spewing their lies on this Sunday morning.
Accumulating Retail investors? This stock is almost fully owned by retails and has been for years. LP herself owns millions of shares as well as other board members and they have been accumulating for years as well.
I believe Linda has an Agreement and it is based on NWBO obtaining approval. With successful preliminary results with the combination trial with Keytruda, why would Merck wait for final results to hammer out the details? The price might or might not be set, but the Agreement has been hammered out.
Merck would not sit idle with any treatment that enhances its #1 best seller and more importantly extends it's patent worth BILLIONS.
Ex, let me provide a quote from the article .
"The vaccine “was shown to prolong life and interestingly so in patients traditionally considered to have poorer prognosis” he added, such as older people and people for whom surgery was not an option.
If approved by medical regulators, the vaccine, DCVax, would be the first new treatment in 17 years for newly diagnosed glioblastoma patients and the first in 27 years for people in whom it had returned."
ASTOUNDING!
Funny, the 70 doctors who coauthored the Journal Article seem to think it is the first trial in 30 years to produce Statistical significance results. What are your qualifications to dispute their findings? Are you like AF? An uncertified Blogger?
Distressed is not the appropriate word. Try manipulated. The only saving grace is, after approval the MM will be unable to control the price and the optics of their foolishness will become a PR nightmare.
Someone picked up a couple of million shares. Gee Wiz Walley, who needs millions of shares? Just some market makers trying to see who will sell at .60. Try again BOYS.
Who do you think paid for their current combo trial with Merck? Did it need another CFO?
Woodford was a looser and he is long gone. Why would his name keep coming up if he has no part in our forward progress?
NWBO is in the dawn of a new era in Cancer treatment. One step away from approval with a very long and positive trial behind us. My only question is after submission, how long will the FDA take to approve DCVax?
The last time I checked, it was LP who got us to this point. Not your Monday quarterbacking.
The only management team to produce a trial with statistical significance in 30 years with rGBM and you call them the worst management team ever? Mind you of course that the 7 market makers you are with picked the best trial in 30 years for rGMM to bet against. Who's calling Who incompetent?
What do you believe the MC will be 5 years post Approval by all 4 RA's?
To the contrary, LP is making a concerted effort to secure approval.
I gave up on Seeking Alpha long ago as to providing reliable investment advice. Unless of course you do the exact opposite of what they recommended.
So I actually like their negative press.
Sure you would like to buy more cheap shares.
According to the Journal Article and 70 co authors, the end point analysis was achieved with statistical significance. Your spin is BS. I look forward to all 4 RA's approving DCVax-L
How long does it take to get actual 5 year survival rates for the cross over patients?
How long does a Journal Article take? How long does it take to set up production? When you look back at what they have had to do to get DCVax -L Approved, it is ridiculous. They are dotting their i's and crossing their "T's".
2 more steps. Submission in the UK and Approval in the UK. Soon, they will also be behind us.
Thanks to your Heggies. Let's see what happens after approval.
I'm almost positive whoever is buying us out is still purchasing shares on the cheap keeping the PPS as low as they can. Then they will throw down 10.00 Per share thinking we will be happy with the buy out price.
DCVax-L is a success. It will be approved by all 4 RA's.
If were not for the 7 "Market Makers" the patients would not have to wait. There are no other treatments that currently work for GBM. The electric hat is only a placebo.
Manipulated from green to red in the last seconds of trading. As always, FOS.
All longs are investors be because of the science. DCVax works and will be approved. However, all longs have seen how the manipulation has impacted NWBO. It's inexcusable and we want revenge and our day in court. I'm sure some new investors look at the lawsuit as a plus. I do for many reasons.
Sorry I'm a Celtics fan from the 80's.
NO NO NO! 20 years in the Pharmaceutical business does NOT mean taking drugs for 20 years!
CRL will take care of production.
Your logic is flawed if you call 70 Coauthors (Doctors) a paid infomercial.
Will the Moon Shot Program be stifled by Congress and Wall Street? Will the FDA be the RA that is left in the dust ? I think NOT.
Not spoofing but ask Martha Stuart about going to Jail.
Legend431 - We are only at .50 because of the efforts of 7 Market Makers. Without these unethical bastards, DCVax-L would be approved and NWBO would be saving patients lives.
Give 500 Million to a school educating lawyers and/or Kill a company curing Cancer. Which is worse? A moral dilemma.